

**September 04, 2023**

**BSE Limited**

Department of Corporate Relationship  
1<sup>st</sup> Floor, New Trade Ring, Rotunda Building  
Phiroze Jeejeebhoy Towers  
Dalal Street, Mumbai- 400001  
*Scrip Code: 524742*

**National Stock Exchange of India Ltd**

Department of Corporate Services  
Exchange Plaza, 5<sup>th</sup> Floor,  
C-1, Block G, Bandra Kurla Complex,  
Bandra (E), Mumbai – 400 051  
*Scrip Code: CAPLIPOINT.*

Dear Sir/Madam,

**Sub: Press Release - Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Attaching herewith a Press Release regarding our Subsidiary Caplin Steriles Limited, which has received Establishment Inspection Report (EIR) from United States Food and Drug Administration (USFDA) for its injectable and ophthalmic manufacturing unit located at Gummidipoondi, Chennai. Request you to take the same on record.

Thanking You,

Sincerely Yours

**For Caplin Point Laboratories Limited**

**Venkatram G**

**General Counsel & Company Secretary**

**Membership No. A23989**

**Encl: A/a**

## Caplin Steriles receives EIR from US FDA

Caplin Steriles Ltd, a subsidiary of Caplin Point Laboratories Ltd, today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (US FDA) for its injectable and ophthalmic manufacturing unit located near Chennai. The unit underwent an inspection from US FDA during May 22<sup>nd</sup> ~ May 31<sup>st</sup> and the inspection classification was determined by the agency as Voluntary Action Indicated (VAI).

### **Commenting on the achievement, Mr. C.C. Paarthipan, Chairman said:**

“This is the fourth US FDA audit at this site and we’re pleased to receive the EIR with a satisfactory outcome. Our commitment to maintaining the highest levels of compliance at all our units remains steadfast. The receipt of EIR will help in receiving continued ANDA approvals for this unit, which is an important growth engine for us”.

### **About Caplin Steriles Limited**

Caplin Steriles Limited, a Subsidiary of Caplin Point Laboratories Limited, is a niche sterile product manufacturing company that is approved by several regulatory agencies such as US FDA. Caplin Steriles Limited, has developed and filed over 31 ANDAs in USA on its own and with partners, with 23 approvals so far. The Company is also working on a portfolio of 55+ simple and complex Injectable and Ophthalmic products, that it intends to file over the next 4 years.

### **About Caplin Point Laboratories Limited:**

Caplin Point Laboratories Limited is a fast-growing pharmaceutical company with a unique business model catering predominantly to emerging markets of Latin America and Africa. Caplin Point is one of the few companies to show consistent high-quality growth in Revenues, Profits and Cash flow over the last 15 years. The Company has state of the art manufacturing facilities that cater to a complete range of finished dosage forms. The Company has also entered regulated markets such as US through its Subsidiary Caplin Steriles Limited.

Caplin Point has been listed on **Forbes “Asia’s 200 Best Under a Billion” list for 2023**. Company has appeared for the sixth time on this list (2014, 2015, 2016, 2021, 2022 and 2023) and was awarded “The Emerging Company of 2018” by Economic Times Family Business Awards.

### **Cautionary Statement:**

*This press release may include statements of future expectations and other forward-looking statements based on management’s current expectations and beliefs concerning future developments and their potential effects upon Caplin Point Laboratories Ltd and its subsidiaries/ associates. These forward-looking statements involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others: general economic and business conditions in India and overseas, our ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currency changes, changes in the Indian and international interest rates, change in laws and regulations that apply to the related industries, increasing competition in and the conditions of the related industries, changes in political conditions in India and changes in the foreign exchange control regulations in India. Neither Caplin Point Laboratories Ltd, nor our directors, or any of our subsidiaries/associates assume any obligation to update any forward-looking statement contained in this release.*

**For further information, please contact:**

**G Venkatram,**  
General Counsel & Company Secretary  
Caplin Point Laboratories

+91 44 2496 8000

[investor@caplinpoint.net](mailto:investor@caplinpoint.net)

**Anvita Raghuram / Rajiv Pandya**  
Churchgate Partners

+91 22 6169 5988

[caplinpoint@churchgatepartners.com](mailto:caplinpoint@churchgatepartners.com)